New strategies for the synthesis of A3 adenosine receptor antagonists

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 19, 2003, Pages 4161-4169

  Baraldi, Pier Giovanni ^a   Bovero, Andrea ^a   Fruttarolo, Francesca ^a   Romagnoli, Romeo ^a   Tabrizi, Mojgan Aghazadeh ^a   Preti, Delia ^a   Varani, Katia ^a   Borea, Pier Andrea ^a   Moorman, Allan R ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b King Pharmaceutical R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(5 AMINO 2 FURAN 2 YLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 8 YL)ACETIC ACID TERT BUTYL ESTER; 1 (3 CHLOROPHENYL) 3 [8 (2,2 DIETHOXYETHYL) 2 FURAN 2 YL 8H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]UREA; 1 [8 (2 BENZYLOXYETHYL) 2 FURAN 2 YL 8H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] 3 PHENYLUREA; 1 [8 (2 HYDROXYETHYL) 2 FURAN 2 YL 8H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] 3 PHENYLUREA; 2 FURAN 2 YL 7H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YLAMINE; 8 (2 HYDROXYETHYL) 2 FURAN 2 YL 8H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YLAMINE; 8 (2,2 DIETHOXYETHYL) 2 FURAN 2 YL 8H PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YLAMINE; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; PYRIMIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; UREA DERIVATIVE; [2 FURAN 2 YL 5 (3 PHENYLUREIDO)PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 8 YL]ACETIC ACID;

ALKYLATION; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ISOMER; SUBSTITUTION REACTION; TECHNIQUE;

EID: 0042890381     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00484-X     Document Type: Article

References (19)

1. Ralevic V., Burnstock G. Pharmacol. Rev. 50:1998;413.
2. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;364.
3. Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., Johnson R.G. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10365.
4. Jacobson K.A., Suzuki F. Drug. Dev. Res. 39:1996;289.
5. Abbracchio M.P., Brambilla R., Kim H.O., von Lubitz D.K., Jacobson K.A., Cattabeni F. Mol. Pharmacol. 48:1995;1038.
6. Ali H., Choi O.H., Fraundorfer P.F., Yamada K., Gonzaga H.M.S., Beaven M.A. J. Pharmacol. Exp. Ther. 276:1996;837.
7. Ramkumar V., Stiles G.L., Beaven M.A., Ali H. J. Biol. Chem. 268:1993;16887.
8. Brambilla R., Cattabeni F., Ceruti S., Barbieri D., Franceschi C., Kim Y., Jacobson K.A., Klotz K.N., Lohse M.J., Abbracchio M.P. Naunyn-Schmiedeberg's Arch. Pharmacol. 361:2000;225.
9. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Klotz K.N., Leung E., Varani K., Gessi S., Merighi S., Borea P.A. J. Med. Chem. 42:1999;4473.
10. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Moro S., Klotz K.N., Leung E., Varani K., Gessi S., Merighi S., Borea P.A. J. Med. Chem. 43:2000;4768.
11. Baraldi P.G., Cacciari B., Moro S., Spalluto G., Pastorin G., Da Ros T., Klotz K.N., Varani K., Gessi S., Borea P.A. J. Med. Chem. 45:2002;770.
12. Schering Corporation, NJ 07033-0530 (US), International Publication Number: WO01/92264 A1, 2001.
13. Dunn L.D., Skinner C.G. J. Org. Chem. 40:1975;3713.
14. Seela F., Steker H. Helv. Chim. Acta. 69:1986;1602.
15. Gatta F., Del Giudice M.R., Borioni A., Borea P.A., Dionisotti S., Ongini E. Eur. J. Med. Chem. 28:1993;569.
16. Varani K., Merighi S., Gessi S., Klotz K.N., Leung E., Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Borea P.A. Mol. Pharmacol. 57:2000;968.
17. Bradfor M.M. Anal. Biochem. 72:1976;248.
18. Cheng Y.C., Prusoff W.H. Biochem. Pharmacol. 22:1973;3099.
19. Munson P.J., Rodbard D. Anal. Biochem. 107:1980;220.